Vertex Pharmaceuticals VRTX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenues, net by Product | ||||||
| ALYFTREK | $1.21B+2,142% | $837.8M— | $457.7M— | $210.7M— | $53.9M— | |
| CASGEVY | $144.5M+497% | $115.8M+1,058% | $69.5M— | $54.6M— | $24.2M— | |
| JOURNAVX | $87.3M+6,615% | $59.6M— | $32.9M— | $13.3M— | $1.3M— | |
| Other CF product revenues | $785.2M+7.6% | $804.6M+3.0% | $758.4M-2.1% | $769.5M-3.5% | $729.8M— | |
| TRIKAFTA/KAFTRIO | $10.13B-1.5% | $10.31B+0.7% | $10.46B+6.2% | $10.39B+8.9% | $10.29B+10.3% | |
| Cost of Sales by Product | ||||||
| Product revenues, net | $631.1M+17.3% | $601.5M+16.5% | $563.1M+24.8% | $555.1M+36.4% | $538.1M+45.2% | |
| Royalty | $1.05B+3.7% | $1.05B+3.5% | $1.05B+7.6% | $1.03B+9.9% | $1.01B+10.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vertex Pharmaceuticals break its business down?
- Vertex Pharmaceuticals (VRTX) reports product revenues, net by product across 5 parts — ALYFTREK, CASGEVY, JOURNAVX, Other CF product revenues and TRIKAFTA/KAFTRIO. Each is extracted from the segment footnotes and tracked over time.
- Where does Vertex Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vertex Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
